Nxera Pharma , Ltd. Other Current Liabilities

The latest other current liabilities for SOLTF is $4.2B as of June 2026. That compares with $3.5B in the prior-year period — up 18.3% year over year. Investors often review this figure alongside Nxera Pharma , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, SOLTF's other current liabilities moved from $3.5B to $4.2B — a 18.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nxera Pharma , Ltd.'s operating scale or balance-sheet position.

A other current liabilities figure of $4.2B for SOLTF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SOLTF's other current liabilities ($4.2B), review year-over-year change from $3.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Nxera Pharma , Ltd.'s other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.